Willingness to participate in HIV vaccine research in a peri-urban South African community

2006 ◽  
Vol 17 (3) ◽  
pp. 176-179 ◽  
Author(s):  
J Smit ◽  
K Middelkoop ◽  
L Myer ◽  
S Seedat ◽  
L-G Bekker ◽  
...  
Keyword(s):  
South African ◽  
Hiv Vaccine ◽  
Sub Saharan Africa ◽  
Willingness To Participate ◽  
Vaccine Research ◽  
Substantial Impact ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials ◽  
Urban South ◽  
African Community

Research on willingness to participate in HIV vaccine trials is important in preparations for HIV vaccine research, but there are few data from sub-Saharan Africa. We interviewed 198 individuals in a peri-urban South African community immediately after enrolment into an HIV vaccine preparedness study on their willingness to participate in hypothetical vaccine trials. Overall 23% of participants ( n = 46) said that they would be willing to participate in an HIV vaccine trial. Willingness was associated with increasing age, male gender, and increasing knowledge about vaccines generally and HIV vaccines specifically. In multivariate analysis, a 1-unit increase in HIV vaccine knowledge score was associated with a 10-fold increase in willingness to participate (adjusted odds ratio, 10.72, 95% confidence intervals: 4.40–26.12). These results suggest that while willingness to participate in HIV vaccine trials is relatively low in this setting, educational campaigns may have a substantial impact on individuals' willingness to participate in research.

Willingness to participate in HIV vaccine trials among HIV-negative gay men in Sydney, Australia

2005 ◽  
Vol 16 (4) ◽  
pp. 314-317 ◽  
Author(s):  
Paul Van de Ven ◽  
Limin Mao ◽  
June Crawford ◽  
Garrett Prestage ◽  
Andrew Grulich ◽  
...  
Keyword(s):  
Gay Men ◽  
Tertiary Education ◽  
Anal Intercourse ◽  
Unprotected Anal Intercourse ◽  
Hiv Vaccine ◽  
Willingness To Participate ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials ◽  
Antibody Positivity ◽  
Hiv Negative

This study aimed to determine and describe HIV-negative gay men's willingness to participate in HIV vaccine trials. Data were from participants who completed face-to-face interviews during the first 18 months (to the end of 2002) of recruitment into the Health in Men cohort of HIV-negative gay men in Sydney. A key outcome measure was a scale of Willingness to Participate in HIV Vaccine Trials, with scores ranging from 1 (unwilling) to 4 (willing). The 903 participants ranged in age from 18 to 75years (median=36). Mean of Willingness to Participate in HIV Vaccine Trials was 2.53 (standard deviation=0.54), with approximately 51% of the men having a score greater than the midpoint of 2.50. A reduced linear regression model yielded four significant independent associations with Willingness to Participate in HIV Vaccine Trials: lack of tertiary education ( P <0.001),having engaged 'in the previous six months' in any unprotected anal intercourse with casual or non-concordant regular partners ( P <0.001), higher self-rated likelihood of HIV infection ( P <0.01), and higher mean scores on a scale of Comfort with Participation in HIV VaccineTrials ( P <0.001). The willingness of HIV-negative gay men at potentially higher risk for HIV to participate in HIV vaccine trials augurs well for enrolment in HIV vaccine efficacy trials. Recruitment into trials is likely to be enhanced by addressing salient concerns such as confidentiality and vaccine-induced antibody positivity. Also, it will be important to ensure that gay men are educated and fully informed about HIV vaccines and trial processes.

scholarly journals Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Maurine D. Miner ◽  
Linda-Gail Bekker ◽  
Tamara Kredo ◽  
Niresh Bhagwandin ◽  
Lawrence Corey ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Hiv Prevention ◽  
South African ◽  
Medical Research Council ◽  
Standard Of Care ◽  
Hiv Vaccine ◽  
Middle Income ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials ◽  
Prevention Trials

AbstractA cornerstone of HIV prevention clinical trials is providing a combination prevention package to all trial participants. The elements included in that standard of care (SoC) package evolve as new prevention modalities are developed. Pre-exposure prophylaxis (PrEP) was recommended by the World Health Organization for persons at high risk of acquiring HIV, but not all countries immediately adopted those recommendations. The South African Medical Research Council (SAMRC) convened a summit to discuss issues relating to SoC and PrEP in HIV prevention clinical trials taking place in lower- to middle-income countries (LMIC). Policymakers, regulators, ethicists, experts in law, researchers, representatives of advocacy groups, and the HIV Vaccine Trials Network (HVTN) presented a framework within which SoC principles could be articulated. A group of subject matter experts presented on the regulatory, ethical, scientific, and historic framework of SoC in clinical trials, focusing on PrEP in South Africa. Summit participants discussed how and when to include new HIV treatment and prevention practices into existing clinical guidelines and trial protocols, as well as the opportunities for and challenges to scaling up interventions. The summit addressed challenges to PrEP provision, such as inconsistent efficacy amongst different populations and various biological, virological, and immunological explanations for this heterogeneity. Advocates and community members propagated the urgent need for accessible interventions that could avert HIV infection. The meeting recommended supporting access to PrEP in HIV prevention trials by (1) developing PrEP access plans for HIV vaccine trials, (2) creating a PrEP fund that would supply PrEP to sites conducting HIV prevention trials via a central procurement mechanism, and (3) supporting the safety monitoring of PrEP. This report summarizes the presentations and discussions from the summit in order to highlight the importance of SoC in HIV prevention clinical trials.

scholarly journals Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials

2012 ◽  
Vol 17 (2) ◽  
pp. 760-772 ◽  
Author(s):  
Barbara Metch ◽  
Ian Frank ◽  
Richard Novak ◽  
Edith Swann ◽  
David Metzger ◽  
...  
Keyword(s):  
At Risk ◽  
Hiv Infection ◽  
Hiv Vaccine ◽  
Willingness To Participate ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials

Willingness to Participate in HIV Vaccine Trials Among Men Who Have Sex With Men in Rio de Janeiro, Brazil

2000 ◽  
Vol 25 (5) ◽  
pp. 459-463 ◽  
Author(s):  
André R.S. Périssé ◽  
Mauro Schechter ◽  
Ronaldo I. Moreira ◽  
Regina F. do Lago ◽  
Guilherme Santoro-Lopes ◽  
...  
Keyword(s):  
Rio De Janeiro ◽  
Hiv Vaccine ◽  
Willingness To Participate ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials ◽  
Sex With Men

Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India

Vaccine ◽  
2014 ◽  
Vol 32 (44) ◽  
pp. 5854-5861 ◽  
Author(s):  
Peter A. Newman ◽  
Venkatesan Chakrapani ◽  
James Weaver ◽  
Murali Shunmugam ◽  
Clara Rubincam
Keyword(s):  
Hiv Vaccine ◽  
Willingness To Participate ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials ◽  
Sex With Men
Sign in / Sign up

Export Citation Format

Share Document